...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy
【24h】

Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy

机译：昂丹西酮治疗失败后可有效与Granisetron交叉使用，这是一项针对高致呕性化疗后头24小时内昂丹西酮加地塞米松治疗失败的患者的随机双盲研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In view of the similarity in chemical structure of the available 5HT3-receptor antagonists it is assumed, whilst these agents all act at the same receptor, that failure to one agent would predict subsequent failure to all 5HT3-receptor antagonists. We conducted a randomized double blind trial of granisetron 3 mg plus dexamethasone 10 mg versus continued treatment with ondansetron 8 mg plus dexamethasone 10 mg in patients with protection failure on ondansetron 8 mg plus dexamethasone 10 mg during the first 24 hours following highly emetogenic chemotherapy. Of 40 eligible patients, 21 received ondansetron + dexamethasone and 19 received granisetron + dexamethasone. We found a significant benefit from crossing-over to granisetron after failure on ondansetron. Of the 19 patients who crossed over to granisetron, 9 patients obtained complete protection, whereas this was observed in 1 of the 21 patients continuing ondansetron, P = 0.005. These results indicate that there is no complete cross-resistance between 5HT3-receptor antagonists, and that patients who have acute protection failure on one 5HT3-receptor antagonist should be offered cross-over to another 5HT3-receptor antagonist. ? 2001 Cancer Research Campaign http://www.bjcancer.com
机译：考虑到可用的5HT 3-受体拮抗剂的化学结构相似，尽管这些试剂均作用于相同的受体，但对一种试剂的失败将预示所有5HT 3-受体拮抗剂的后续失败。我们对高度呕吐化疗后的最初24小时内对恩丹西酮8 mg加地塞米松10 mg的保护失败的患者进行了格拉司琼3 mg加地塞米松10 mg与恩丹西酮8 mg加地塞米松10 mg继续治疗的随机双盲试验。在40例合格患者中，有21例接受了恩丹西酮+地塞米松治疗，而19例接受了Granisetron +地塞米松治疗。我们发现在恩丹西酮失败后，转用Granisetron有很大的好处。在19名交叉使用Granisetron的患者中，有9名患者获得了完全的保护，而21名继续使用昂丹司琼的患者中有1名观察到这一点，P = 0.005。这些结果表明，5HT3受体拮抗剂之间没有完全的交叉耐药性，对一种5HT3受体拮抗剂的急性保护失败的患者应与另一种5HT3受体拮抗剂交叉使用。 ？ 2001年癌症研究运动http://www.bjcancer.com

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号